Visual Recognition of Allergens by Allergic Patients and/or Their Parents

Status Completed

Clinical Trial Summary

Food allergies are constantly increasing. Peanut and nut allergies are a major cause of allergic reactions. Diagnosed patients are also at risk, because 27% of the patients that had an allergic reaction have another one in the following year with the same food, despite a real improvement in industrial products labeling.

The investigators have observed in the allergy Unit that patients (and/or their family) following an elimination diet, sometimes since several years, use very strict elimination strategies. Those strategies sometimes lead to incapacities to recognize the allergens. Yet, a good identification of the allergen is the key to a successful elimination and the non-identification a known risk factor.

Ferdman shown in 2006 that 27% of the patients didn't recognize the allergen there were allergic to. However, this is a US study, and geographical specificities have an impact on food consumption and culture. Food allergology needs to take those two elements into account. For example, in France, a single food can have two names. It is the case of peanut, which can be called "arachide", or more frequently "cacahuète".

The goal of the study is to observe patient aptitudes to recognize peanut (and the association between the two names) and other nuts available in France and define by the European law, using a plate with various food samples in seed or in shell.

Thus, patients in care at the allergy Unit of Saint Vincent Hospital of Lille (France) and their families were surveyed with a standardized procedure at the beginning of their therapeutic education and their capacity to recognize various nuts, to identify peanut ("cacahuète" or "arachide") and to associate the two words "cacahuète" and "arachide" was assessed. It is a standard procedure in therapeutic education, and the responses have been systematically entered in the medical record.

The main objective of this study is to describe peanut or nut allergic patient capacity (adult, children and/or the family) to visually identify the foods there are allergic to.

The secondary objective of this study is to describe the capacity of patient that describe themselves as allergic to "arachide" to associate this word to the word "cacahuète".

Clinical Trial Description

n/a

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02966938
Study type	Observational
Source	Lille Catholic University
Contact
Status	Completed
Phase	N/A
Start date	December 2015
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05667610` - Immune-supportive Diet and Gut Permeability in Allergic Children	N/A
Recruiting	`NCT05440643` - Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy	Phase 1
Terminated	`NCT03849079` - Validation of the HYPONUT Product	N/A
Completed	`NCT02979600` - Clinical and Biological Efficacy of Peanut Oral Immunotherapy	N/A
Completed	`NCT01955109` - Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children	Phase 2
Completed	`NCT01950533` - The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
Recruiting	`NCT04415593` - High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety	N/A
Active, not recruiting	`NCT04511494` - Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT	N/A
Active, not recruiting	`NCT04887441` - Allergology: Information, Data and Knowledge Organization
Active, not recruiting	`NCT04881773` - Oral Low Doses Tolerance INduction Study for Peanuts
Completed	`NCT03682770` - Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)	Phase 2
Terminated	`NCT03703791` - Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents	Phase 3
Completed	`NCT02916446` - Safety Study of Viaskin Peanut to Treat Peanut Allergy	Phase 3
Active, not recruiting	`NCT02402231` - Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy	Phase 2
Completed	`NCT03337542` - AR101 Real-World Open-Label Extension Study	Phase 3
Recruiting	`NCT05476497` - Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects	Phase 1
Completed	`NCT03648320` - The Grown Up Peanut Immunotherapy Study	N/A
Completed	`NCT03292484` - Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)	Phase 3
Completed	`NCT03852342` - Reactive Doses and Times During Oral Food Challenge to Peanut
Recruiting	`NCT05138757` - Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Visual Recognition of Allergens by Allergic Patients and/or Their Parents — REVIALL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms